DRCPTR: Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis

Sponsor

University of Brasilia (Other)

Overall Status

Completed

CT.gov ID

NCT02249884

Collaborator

University of Washington (Other)

Enrollment

Location

Arms

Duration (Months)

1.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Dose response curve to define the security and tolerable dose to be used for prevention and treatment of radiodermatitis in patients with breast or head and neck cancer.

Condition or Disease	Intervention/Treatment	Phase
Radiodermatitis	Drug: Urea Dose A Drug: Urea Dose B Drug: Urea Dose C Drug: Chamomile Dose A Drug: Chamomile Dose B Drug: Chamomile Dose C	Phase 2

Detailed Description

The study is being conducted in Center for High Complexity Oncology (CACON) located at the University Hospital of Brasília (HUB). Has as its target population subjects diagnosed with breast and head and neck cancer undergoing radiotherapy. Three doses of urea cream are being tested. Participants are subjected to simple randomization technique, in which the members of the study are directly allocated in groups set forth, without any intermediate step. Patients are identified, go to a nursing consultation for general orientations about treatment. After the consultation, patients are invited to participate in the study. The patient should express its acceptance through the informed consent form. Data are being collected through interviews and medical records. Patients are being evaluated during three weeks, considering the toxicity of the intervention and the beginning of radiodermatitis. To evaluate the skin reaction will be applied scale of the Radiation Therapy Oncology Group (RTOG) - Acute Radiation Morbidity Scoring Criteria, Common Terminology Criteria for Adverse Events (CTCAE) and Radiation-Induced Skin Reaction Assessment Scale (RISRAS). For reliable assessment and record of the evolution throughout the treatment and study, patients will be photographed weekly (D0, D5, D10, D15). Will be photographed major regions subject to evaluation: frontal, right side profile and left side profile with Photographic camera Nikon P510. The data will be inserted into Statistical Package for Social Sciences (SPSS), version 18.0, for the analysis.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Outcomes Assessor)

Official Title:

Use of Chamomilla Recutita Gel and Urea Cream to Prevent and Treat Radiodermatitis: Phase 2 Study

Study Start Date :

Feb 1, 2014

Actual Primary Completion Date :

Mar 1, 2015

Actual Study Completion Date :

Nov 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Urea Dose A Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.	Drug: Urea Dose A Urea cream for topical use. Other Names: Urea cream
Experimental: Urea Dose B Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.	Drug: Urea Dose B Urea cream for topical use. Other Names: Urea cream
Experimental: Urea Dose C Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.	Drug: Urea Dose C Urea cream for topical use. Other Names: Urea cream.
Experimental: Chamomile Dose A Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.	Drug: Chamomile Dose A Chamomile gel for topical use. Other Names: Chamomile gel
Experimental: Chamomile Dose B Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.	Drug: Chamomile Dose B Chamomile gel for topical use. Other Names: Chamomile gel
Experimental: Chamomile Dose C Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.	Drug: Chamomile Dose C Chamomile gel for topical use. Other Names: Chamomile gel

Outcome Measures

Primary Outcome Measures

Time of occurrence of Radiodermatitis [3 weeks]
Time of occurrence of Radiodermatitis according with the Radiation Therapy Oncology Group (RTOG).

Secondary Outcome Measures

Indicators of toxicity [3 weeks]
Evaluate the tolerance and safety of the intervention according to the assessment of toxicity during the intervention. To evaluate the toxicity will be considered signs and symptoms referable to the region of application of the product, such as skin rash, urticaria, vesicles, blisters, pustules, as well as the patient's report of discomfort, burning, stinging and itching.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Being an adult, over the age of 18 years old
Owning diagnosis of breast or head and neck cancer
Being first referred to the radiotherapy protocol
Have absence of radiodermatitis and integrates skin to start radiotherapy
Not have presented anticipated reaction of hypersensitivity to chamomile or any plant of the family Asteraceae or Compositae or urea.
Demonstrate conditions to continue the intervention in their home environment when needed.